COVID-19 Vaccination Plan

South Dakota Department of Health
March 2, 2021

We will begin in just a few moments. Thanks!
Information is current as of 03.01.2021

Not intended for press or for reporting purposes.
This is an **emerging, rapidly evolving situation**. Information in this presentation is current as of March 01, 2021. Please check the South Dakota Department of Health website for the most current information and guidance.

COVID.sd.gov

*Not intended for press or for reporting purposes.*
Agenda

Update on Vaccination – Tim Heath

SDIIS Updates – Brett Oakland

Training Update – Carol Chalcraft
Update on Vaccination
# Doses Administered

## Total DosesAdministered

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th># of Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderna</td>
<td>113,541</td>
</tr>
<tr>
<td>Pfizer</td>
<td>110,257</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total Persons Administered a Vaccine</th>
<th># of Recipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderna - 1 dose</td>
<td>36,621</td>
</tr>
<tr>
<td>Moderna - Series Complete</td>
<td>38,460</td>
</tr>
<tr>
<td>Pfizer - 1 dose</td>
<td>32,109</td>
</tr>
<tr>
<td>Pfizer - Series Complete</td>
<td>39,074</td>
</tr>
</tbody>
</table>

## Percent of State Population with at least 1 Dose

- **Doses**: 146,264
- **% of Pop.**: 26%

<table>
<thead>
<tr>
<th>Doses</th>
<th>% of Pop.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 dose</td>
<td>25.63%</td>
</tr>
<tr>
<td>Series Complete</td>
<td>13.33%</td>
</tr>
</tbody>
</table>

*Based on 2019 Census Estimate for those aged 16+ years. Includes aggregate data on IHS and federal entities.*

---

Not intended for press or for reporting purposes.
# SD DOSES Received

<table>
<thead>
<tr>
<th>Vaccine Type</th>
<th>Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer 1</td>
<td>70,785</td>
</tr>
<tr>
<td>Pfizer 2</td>
<td>52,455</td>
</tr>
<tr>
<td>Moderna 1</td>
<td>80,100</td>
</tr>
<tr>
<td>Moderna 2</td>
<td>55,200</td>
</tr>
<tr>
<td>Janssen</td>
<td>7,000</td>
</tr>
<tr>
<td>LTC Pharm/Retail PHarm</td>
<td>24,050</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>289,590</strong></td>
</tr>
</tbody>
</table>
**SD DOSES Received**

<table>
<thead>
<tr>
<th>Description</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>This Week's 1(^{st}) dose shipments</td>
<td>27,000</td>
</tr>
<tr>
<td>This Week's 2(^{nd}) dose Shipments</td>
<td>15,890</td>
</tr>
<tr>
<td>Doses At Pharmacy</td>
<td>9,976</td>
</tr>
<tr>
<td>Second Dose to be given this week</td>
<td>15,190</td>
</tr>
</tbody>
</table>

*Not intended for press or for reporting purposes.*
Weekly 1st Doses Projected

Pfizer  10,530

Moderna  8,300
Bonus Doses

Pfizer vaccine yields 6 doses – this will be a label change

Moderna vaccine may yield 1 or 2 extra doses

DO NOT POOL VACCINE FROM MULTIPLE VIALS
## Priority groups


<table>
<thead>
<tr>
<th>Group</th>
<th>Total</th>
<th>Vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td>1A</td>
<td>19,265</td>
<td>22,916</td>
</tr>
<tr>
<td>1B</td>
<td>10,867</td>
<td>2,980</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vaccinated-not including CVS/Walgreens (5807)</td>
</tr>
<tr>
<td>1C</td>
<td>49,642</td>
<td>23,634</td>
</tr>
<tr>
<td>1D</td>
<td>265,561</td>
<td>67,197</td>
</tr>
<tr>
<td>1E</td>
<td>227,448</td>
<td></td>
</tr>
</tbody>
</table>

*Not intended for press or for reporting purposes.*
# Expected COVID-19 Vaccine Availability for South Dakota Residents

<table>
<thead>
<tr>
<th>Phase</th>
<th>Population Group</th>
<th>January</th>
<th>February</th>
<th>March</th>
<th>April</th>
<th>May-December</th>
</tr>
</thead>
<tbody>
<tr>
<td>1A</td>
<td>Frontline healthcare workers and long-term care facility healthcare workers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1B</td>
<td>Long-term care residents</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1C</td>
<td>EMS, public health workers, and other healthcare workers (lab &amp; clinic staff)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Law enforcement, correctional officers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1D</td>
<td>Persons aged 65 years and older</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>High risk patients - dialysis, post-transplant, and active cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>High risk residents in congregate settings</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Persons with underlying medical conditions under the age of 65</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Teachers and other school/college staff</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Funeral service workers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1E</td>
<td>Fire service personnel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Includes public-facing workers in essential and critical infrastructure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase 2</td>
<td>All others 16 years and older</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Estimated Vaccine Availability**

Note: Tribal vaccine allocation & administration is handled by the USD.
Veteran vaccine allocation & administration is handled by the VA.

---

Not intended for press or for reporting purposes.

South Dakota: All Federal Pharmacy Partners

- CVS
- Walgreens
- Walmart
- Rite Aid
- Kroger Corporate Pharmacy
- Albertsons
- Publix Super Markets
- Retail Business Services
- COSTCO
- H-E-B
- Hy-Vee
- Meijer Pharmacy
- Southeastern Grocers
- PharMerica
- Lewis Drug

DRAFT – PRE-DECISIONAL & DELIBERATIVE

Not intended for press or for reporting purposes.
## Federal Partners in SD (72,705 ordered)

<table>
<thead>
<tr>
<th></th>
<th>First Dose</th>
<th>Second Dose</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>BOP</td>
<td>100</td>
<td>97</td>
<td>197</td>
</tr>
<tr>
<td>VA</td>
<td>12,199</td>
<td>5,723</td>
<td>17,922</td>
</tr>
<tr>
<td>IHS</td>
<td>18,099</td>
<td>9,545</td>
<td>27,644</td>
</tr>
<tr>
<td>DOD</td>
<td>2,243</td>
<td>1,075</td>
<td>3,318</td>
</tr>
<tr>
<td>Totals</td>
<td>32,641</td>
<td>16,440</td>
<td>49,081</td>
</tr>
</tbody>
</table>

*Not intended for press or for reporting purposes.*
Janssen/Johnson & Johnson Vaccine

- FDA and ACIP have approved
- Viral Vector vaccine
- 5 dose vials
- Refrigerator temps for shipping and storage
SDIIS Updates
South Dakota Immunization Information System (SDIIS)

• **SDIIS Training:** [https://doh.sd.gov/COVID/Vaccine/Providers.aspx](https://doh.sd.gov/COVID/Vaccine/Providers.aspx)

  - The following trainings are available for new users and serve as a review for skilled users. Data Entry staff, whether vaccinators or ancillary staff, should view, at minimum, Trainings 1, 2, and 3. Staff tasked with Data Entry and Inventory Management, e.g. Vaccine Coordinators, should view all SDIIS trainings.

• **User Application** (next slide)

  1. [Login and Settings](#) (updated 12/02/20)
  2. [Search for Patients and Edit Information](#) (updated 02/08/21)
  3. [Give Vaccine](#) (updated 01/11/21)
  4. [Ordering and Receiving](#) (updated 02/01/21)
  5. [Inventory Management](#) (updated 12/28/20)
     5a. [Wastage Reconciliation](#) (01/26/21)
  6. [Vaccine Transfer](#) (updated 01/12/21)
  7. [Patient Detail Report](#) (01/05/21)

*Not intended for press or for reporting purposes.*
South Dakota Immunization Information System (SDIIS)

• **SDIIS User Access Application**
  - **UPDATED:**
  - Used to request access for new users to SDIIS
  - Used for those who need view/enter data into the SDIIS
  - **NEW:** Section regarding vaccinator status
  - Has been added to Provider Education website
  - [https://doh.sd.gov/COVID/Vaccine/Providers.aspx](https://doh.sd.gov/COVID/Vaccine/Providers.aspx)

Not intended for press or for reporting purposes.
South Dakota Immunization Information System (SDIIS)

• **COVID-19 Vaccine Data Entry Reminders**
  - Use simple search parameters when searching for patients in SDIIS.
    - Use first initial and birthdate, or
    - Use first three letters of first and last name
    - Remember to consider given name vs. nickname – e.g. James vs. Jim
    - Spaces and punctuation = extra characters = different spelling
      - e.g. VAN, Mc, O’ – One word vs. multiple words
    - Please ensure that the **name and birthdate match** the person who is vaccinated. Check address and phone, anything to help confirm patient identity
    - Avoid creating duplicate records.
    - If multiple patient searches come up empty, then you may **ADD NEW PATIENT**
  
  - When selecting priority group, **DO NOT select Priority Group “2nd Dose”** if patient record does not already have one dose. If you know the patient received a first dose, but you don’t see it, then you don’t have the right record.
  - Ensure that the 2nd dose of COVID-19 vaccine is the same brand as the first dose
  
- **ALL COVID-19 vaccine records in SDIIS must have an ADDRESS** (City, State, Zip, County)
- **ALL COVID-19 vaccine records in SDIIS must include** GENDER, RACE, ETHNICITY (Hispanic Origin in SDIIS)

---

*Not intended for press or for reporting purposes.*
• **New COVID-19 Vaccine**
  - **COVID-19-JAN**
  - One dose only!

Not intended for press or for reporting purposes.
Training Update
NEEDED: Education Attestations

• Thanks to all providers who have submitted Education Attestations

• If your provider site has not submitted the Attestation, please do ASAP

• If you need assistance with submitting the Attestation, please contact me.
Janssen COVID-19 Vaccine Granted Emergency Use Authorization (EUA)

- The Janssen COVID-19 Vaccine is authorized for use in individuals 18 years of age and older
- The Janssen COVID-19 Vaccine is administered intramuscularly as a single dose (0.5 ml.) No dilution needed.
- [https://www.janssencovid19vaccine.com/](https://www.janssencovid19vaccine.com/)
- Phone: 1-800-565-4008 (toll free) or 908-455-9922
- Vaccine expiration check: [www.vaxcheck.jnj](http://www.vaxcheck.jnj)
The Janssen COVID-19 Vaccine is administered intramuscularly as a single dose (0.5 mL)

- 10 vials per box
- 5 doses (0.5ml) per vial

Not intended for press or for reporting purposes.
Storage and Handling

• Unpunctured multi-dose vials of the Janssen COVID-19 Vaccine at 2°C to 8°C (36°F to 46°F) and protect from light. May be stored for up to 3 months. Check expiration date. Do not store frozen.

• **Unpunctured** vials of Janssen COVID-19 Vaccine may be stored at room air for up to **12 hours**

• **Punctured vials of the Vaccine** may be stored between 2°C to 8°C (36°F to 46°F) for up to **6 hours**

• **Punctured vials may be stored at room temperature** (maximally 25°C/77°F) for up to **2 hours**

*Discard the vial if vaccine is not used within these times.*
Janssen COVID-19 Vaccine Storage

• The Janssen COVID-19 Vaccine is initially stored frozen by the manufacturer, then shipped at 2°C to 8°C (36°F to 46°F).

• If vaccine is still frozen upon receipt, thaw at 2°C to 8°C (36°F to 46°F).

• If needed immediately, thaw at room temperature (maximally 25°C/77°F).

• A carton of 10 vials will take approximately 2 hours to thaw

• An individual vial will take approximately 1 hour to thaw. *Do not refreeze once thawed.*
Dose Preparation

- The Janssen COVID-19 Vaccine is a colorless to slightly yellow, clear to very opalescent suspension.

- Prior to administration visually inspect the Janssen COVID-19 Vaccine vials for particulate matter and discoloration. If either of these conditions exists, do not administer the vaccine.

- Before withdrawing each dose of vaccine, carefully mix the contents of the multi-dose vial by swirling gently in an upright position for 10 seconds. Do not shake.

- Each dose is 0.5 mL. Each vial contains five doses. Do not pool excess vaccine from multiple vials.

- The Janssen COVID-19 Vaccine does not contain a preservative.

- Record the date and time of first use on the Janssen COVID-19 Vaccine vial label.
CONTRAINDICATION

Do not administer the Janssen COVID-19 Vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Janssen COVID-19 Vaccine (see Full EUA Prescribing Information).

Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Janssen COVID-19 Vaccine.

Monitor Janssen COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines:

- 15 minutes wait after vaccine for recipients with no history of allergic reaction to anything
- 30 minutes for those with history of allergic reaction to anything

Not intended for press or for reporting purposes.
Clinician Outreach and Communication Activity (COCA)

• COCA prepares clinicians to respond to emerging health threats and public health emergencies by communicating relevant, timely information related to disease outbreaks, disasters, terrorism events, and other health alerts.

Learn more about COCA
What Clinicians Need to Know About Johnson & Johnson’s Janssen COVID-19 Vaccine

When:
Tuesday, March 2, 2021,
12:00 PM – 1:00 PM CST

Webinar Link:
https://www.zoomgov.com/j/1603748312?pwd=anlmUURkSEtmdzBLSmNOV0pJSzZUQT09external icon
Passcode: 893944
Dial In:
US: +1 669 254 5252
or +1 646 828 7666
or +1 551 285 1373
or +1 669 216 1590

Not intended for press or for reporting purposes.
Janssen COVID-19 Webinars available:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mon, Mar 8, 2021</td>
<td>12:00 PM CT</td>
<td>Janssen COVID-19 Vaccine: Information for Healthcare Providers Administering Vaccine</td>
<td>Rick Nettles, MD</td>
<td>▶ Schedule Now</td>
</tr>
<tr>
<td>Tue, Mar 9, 2021</td>
<td>6:00 PM CT</td>
<td>Janssen COVID-19 Vaccine: Information for Healthcare Providers Administering Vaccine</td>
<td>Rick Nettles, MD</td>
<td>▶ Schedule Now</td>
</tr>
<tr>
<td>Wed, Mar 10, 2021</td>
<td>2:00 PM CT</td>
<td>Janssen COVID-19 Vaccine: Information for Healthcare Providers Administering Vaccine</td>
<td>Rick Nettles, MD</td>
<td>▶ Schedule Now</td>
</tr>
<tr>
<td>Thu, Mar 11, 2021</td>
<td>6:00 PM CT</td>
<td>Janssen COVID-19 Vaccine: Information for Healthcare Providers Administering Vaccine</td>
<td>Rick Nettles, MD</td>
<td>▶ Schedule Now</td>
</tr>
<tr>
<td>Fri, Mar 12, 2021</td>
<td>12:00 PM CT</td>
<td>Janssen COVID-19 Vaccine: Information for Healthcare Providers Administering Vaccine</td>
<td>Rick Nettles, MD</td>
<td>▶ Schedule Now</td>
</tr>
<tr>
<td>Mon, Mar 15, 2021</td>
<td>2:00 PM CT</td>
<td>Janssen COVID-19 Vaccine: Information for Healthcare Providers Administering Vaccine</td>
<td>Rick Nettles, MD</td>
<td>▶ Schedule Now</td>
</tr>
<tr>
<td>Tue, Mar 16, 2021</td>
<td>6:00 PM CT</td>
<td>Janssen COVID-19 Vaccine: Information for Healthcare Providers Administering Vaccine</td>
<td>Rick Nettles, MD</td>
<td>▶ Schedule Now</td>
</tr>
</tbody>
</table>

Not intended for press or for reporting purposes.
Janssen COVID-19 vaccine key messages:

- Janssen’s vaccine has been shown to prevent severe COVID-19 illness, hospitalization, and death and is another tool to help combat COVID-19.

- The vaccine was studied in multiple countries, including South Africa and Brazil, both places where variants of COVID-19 have emerged.

- The different types of vaccines were not studied in head-to-head comparisons or trials; therefore, they should not be compared to each other.
Healthcare providers are **required by law to report** to **VAERS**
- Any adverse event listed in the **VAERS Table of Reportable Events Following Vaccination** that occurs within the specified time period after vaccination
- An adverse event listed by the vaccine manufacturer as a contraindication to further doses of the vaccine

Healthcare providers are **strongly encouraged to report**:
- Any adverse event that occurs after the administration of a vaccine licensed in the United States, whether or not it is clear that a vaccine caused the adverse event
- Vaccine administration errors
For COVID-19 Vaccines

The vaccination provider is responsible for **mandatory** reporting of the following to the Vaccine Adverse Event Reporting System (VAERS):

• vaccine administration errors whether or not associated with an adverse event

• serious adverse events* (irrespective of attribution to vaccination)

• cases of Multisystem Inflammatory Syndrome (MIS) in adults

• cases of COVID-19 that result in hospitalization or death.

*Not intended for press or for reporting purposes.
Serious adverse events are defined as:

- Death
- A life-threatening adverse event
- Inpatient hospitalization or prolongation of existing hospitalization
- A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
- A congenital anomaly/birth defect
- An important medical event that based on appropriate medical judgement may jeopardize the individual and may require treatment
Amendment to the Pfizer EUA


- Added an alternative option for frozen storage and transportation at -25°C to -15°C (-13°F to 5°F)

- Frozen vials stored or transported at -25°C to -15°C (-13°F to 5°F) may be returned one time to the recommended storage condition of -80°C to -60°C (-112°F to -76°F).

- Total cumulative time the vials are stored at -25°C to -15°C (-13°F to 5°F) should be tracked and should not exceed 2 weeks.

Not intended for press or for reporting purposes.
Healthcare Provider and Recipient Fact Sheets Changes (PFIZER)

**HCP Fact Sheet:**
- Pregnancy risk summary updated to include data from reproductive and developmental toxicity study in rats.
- New section 6.2 Post Authorization Experience (includes anaphylaxis and severe allergic reactions)
- Updated CDC link to anaphylaxis guidance

**Recipient Fact Sheet:**
- Added to list of adverse events: non-severe allergic reactions such as rash, itching, hives, or swelling of the face and severe allergic reactions

*Not intended for press or for reporting purposes.*
Contact Information

Angela Jackley  Deputy Administrator, Office of Disease Prevention Services.  Vaccination Lead

Tim Heath  Immunization Program Coordinator, Vaccination co-lead  tim.heath@state.sd.us

Brett Oakland  Immunization Registry Coordinator  brett.oakland@state.sd.us

Carol Chalcraft  Immunization Education Coordinator  carol.chalcraft@state.sd.us

Misty Pickner  Vaccine Management Specialist  misty.pickner@state.sd.us

Not intended for press or for reporting purposes.